Scientific breakthroughs don’t always happen in labs. For Sophia and Richard Lunt, Michigan State University researchers, many of their breakthroughs happen during neighborhood walks.
The married couple’s step-by-step approach has revealed a new way to detect and attack cancer cells using technology traditionally reserved for solar power. The results, published in the current issue of Scientific Reports, showcases dramatic improvements in light-activated fluorescent dyes for disease diagnosis, image-guided surgery and site-specific tumor treatment.
“We’ve tested this concept in breast, lung cancer and skin cancer cell lines and mouse models, and so far it’s all looking remarkably promising,” said Sophia, MSU biochemistry and molecular biologist.
While the cancer applications hold the most possibility, their findings have potential beyond the field of oncology, said Richard, the Johansen Crosby Endowed Professor of chemical engineering and materials science.
“This work has the potential to transform fluorescent probes for broad societal impact through applications ranging from biomedicine to photocatalysis – the acceleration of chemical reactions with light,” he said. “Our solar research inspired this cancer project, and in turn, focusing on cancer cells has advanced our solar cell research; it’s been an amazing feedback loop.”
Prior to the Lunts’ combined effort, fluorescent dyes used for therapeutics and diagnostics, aka “theranostics,” had shortcomings, such as low brightness, high toxicity to cells, poor tissue penetration and unwanted side effects.
By optoelectronically tuning organic salt nanoparticles used as theranostics, the Lunts were able to control them in a range of cancer studies. Coaxing the nanoparticles into the nontoxic zone resulted in enhanced imaging, while pushing them into the phototoxic – or light-activated – range produced effective on-site tumor treatment.
The key was learning to control the electronics of their photoactive molecules independently from their optical properties and then making the leap to apply this understanding in a new way to a seemingly unrelated field.
Richard had recently discovered the ability to electronically tune these salts from his work in converting photovoltaics into solar glass.
Sophia had long studied metabolic pathways unique to cancer cells. It was when the Lunts were discussing solar glass during a walk that they made the connection: Molecules active in the solar cells might also be used to more effectively target and kill cancer cells.
A journey of 1,000 miles
Their walks had rather unscientific beginnings. Shortly after the Lunts met at Princeton University, Richard moved to another university. To maintain their long-distance relationship, they scheduled daily phone calls. Upon their arrival at MSU, individual academic career demands replaced geographic distance as a challenge to their busy lives.
To connect daily, they take CEO-style walks together every evening. The two-mile saunters take place rain or shine, and they often engage in scientific discussions. The three keys to their walks are intentional curiosity, perseverance and the merging of different fields and perspectives, Sophia said.
“We talk science, strategic plans for our careers and our various grants,” she said. “We ping ideas off each other. Our continual conversations brainstorming ideas on a particular topic or challenge often lead to those exciting ‘aha’ moments.”
Their walks have helped them push through many challenges.
“Our first experiments did not turn out as expected; I’m surprised that we didn’t give up given how crazy the idea seemed at first,” Richard said. “Figuring out how to do this research took many walks.”
Obviously, the results were worth the hike. Today, Richard designs the molecules; Babak Borhan, MSU chemist, synthesizes and improves them; and Sophia tests their photoactive inventions in cancer cell lines and mouse models.
Future research will work to improve the theranostics’ effectiveness, decrease toxicity and reduce side effects. The Lunts have applied for a patent for their work, and they’re looking forward to eventually pushing their photoactive molecule findings through clinical trials.
“Though that will take many more walks,” Richard said with a smile.
Learn more: CAN SOLAR TECHNOLOGY KILL CANCER CELLS?
The Latest on: Theranostics
[google_news title=”” keyword=”theranostics” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Theranostics
- New guidelines shape the future of neuroendocrine tumor managementon April 30, 2024 at 12:25 pm
Newly updated guidelines on neuroendocrine tumors developed by an expert at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborators provide ...
- Spectrum and Hermes Medical Solutions to offer vendor-neutral softwareon April 29, 2024 at 6:09 am
S pectrum Dynamics Medical and Hermes Medical Solutions have announced a partnership to deliver an integrated solution of the Hermia software with the former’s VERITON-CT scanner.
- Ed Ness: Healthcare trends and transformation in the year aheadon April 27, 2024 at 5:00 pm
Theranostics and BiTE therapy are underway at Cowell Family Cancer Center with plans to add to the services provided as we head toward 2025. We’ve also added dozens of primary care providers across ...
- APCCC 2024: PSMA Radioligand Therapy – State of the Arton April 27, 2024 at 6:35 am
(UroToday.com) The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) held in Lugano, Switzerland between April 25 th and 27 th was host to PSMA for Diagnostic and Treatment session. Dr. Ken ...
- AUA 2024: Awaiting New Data in the Treatment of Metastatic Prostate Canceron April 26, 2024 at 1:59 pm
Cite this: AUA 2024: Awaiting New Data in the Treatment of Metastatic Prostate Cancer - Medscape - Apr 26, 2024.
- Monument Health invests in future of nuclear pharmacy in Rapid Cityon April 24, 2024 at 10:51 pm
RAPID CITY, S.D. (KOTA) - Last month Monument Health opened its nuclear pharmacy facility. The building joins a facility in Sioux Falls as the only two of their kind in South Dakota. But what does ...
- Cancer Theranostics With Gold Nanoshellson April 19, 2024 at 4:59 pm
AuNSs generate heat as a result of irradiation by a continuous laser. The temperature increase (ΔT) depends on the laser power and AuNS concentration. Both high-temperature thermal ablation and ...
- MoneyTalks: Pointsbet exits US business, will gain market share in Australia says brokeron April 15, 2024 at 11:33 pm
Clarity Pharma is set to gain from clinical trial results, while Pointsbet could take market share in Australia.
- Aptamer-based theranostics in oncologyon April 14, 2024 at 5:00 pm
Aptamer-based theranostics have gained attention in the field of cancer research and treatment. Aptamers can be used as targeting ligands for the delivery of therapeutic agents to cancer cells ...
- Outlining the future of theranostics in neurooncologyon February 15, 2024 at 12:17 pm
More information: Nelleke Tolboom et al, Theranostics in Neurooncology: Heading Toward New Horizons, Journal of Nuclear Medicine (2023). DOI: 10.2967/jnumed.123.266205 Provided by Society of ...
via Bing News